“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Laboratorios Grin, Lupin’s subsidiary in Mexico, remains one of the key players in the Ophthalmic segment and continues to deliver steady growth. In the past 12 months, despite the manufacturing plant being shut for seven months, revenues grew by 5%, with sales of MXP 674 million delivering a healthy increase on all profitability parameters above industry benchmarks.
The Company launched two preservative-free ophthalmic soutions for the treatment of Glaucoma. The Mexican pharmaceutical market is expected to grow mainly in the Antiviral, Diabetes, Oncology and Cardio-Metabolic therapeutic areas with a shift towards greater export diversity.